1st Alzheimer’s Patient Dosed in Clinical Trial of Amyloid Beta ‘Displacer’

1st Alzheimer’s Patient Dosed in Clinical Trial of Amyloid Beta ‘Displacer’
cognitionlogoCognition Therapeutics has announced the dosing of the first Alzheimer's patient in a Phase 1b clinical trial of its drug candidate, CT1812, for the treatment of mild to moderate Alzheimer's disease (AD). CT1812 is a proprietary, first-in-class, orally available, drug-like small molecule designed to displace bound amyloid beta oligomers (molecules thought to be key agents in the onset of Alzheimer's disease). It inhibits the binding of amyloid beta oligomers to the receptor complex. By competing with amyloid beta oligomers for critical receptor targets, CT1812 works to both target and displace the toxic protein and prevent the damage its buildup can cause. CT1812 has been shown to stop and reverse memory loss in preclinical Alzheimer's disease models, the company reported. In a Phase 1a study (NCT02570997), the drug was also found to be safe at multiple ascending dose levels in 94 healthy volunteers, 74 of whom were on a once daily CT1812 oral dosing schedule for up to two weeks. The randomized and placebo-controlled  Phase 1b trial (NCT02907567) is designed to evaluate the safety, tolerability and pharmacokinetic profile of CT1812 in mild to moderate AD patients. Enrolled participants will be randomized to one of two doses (280mg or 560mg) daily for 28 days, or to placebo. Results, expected in mid-2017, will help to inform a  larger Phase 2 study of CT1812 in s
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *